- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
U.S. military issues big MRI award
The red-hot MRI market got a boost from the U.S. military last month after the Department of Defense's purchasing agency issued an award to six vendors for the acquisition of MRI equipment over the next year. The Defense Support Center Philadelphia named
The red-hot MRI market got a boost from the U.S. military last month after the Department of Defense's purchasing agency issued an award to six vendors for the acquisition of MRI equipment over the next year. The Defense Support Center Philadelphia named GE, Picker, Siemens, Philips, Toshiba, and Lunar as the companies that are eligible to compete for contracts each time an order comes in to the DSCP for an MRI system or accessory. The DOD estimates that it will spend about $40 million on MRI technology over the next year, an amount that will be split among the six companies. The award comes with an option to extend the contract over the next four years, according to a DSCP spokesperson.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
